Abstract
Purpose:
The pharmacokinetics of etoposide were studied in cancer patients with brain metastases treated with high-dose etoposide in order to determine if the pharmacokinetics were altered by the use of dexrazoxane as a rescue agent to reduce the extracerebral toxicity of etoposide.
Methods:
Etoposide plasma levels were determined by HPLC.
Results:
The etoposide pharmacokinetics described by a monophasic first-order elimination model were found to be similar to other reported data in other settings and at similar doses.
Conclusions:
The pharmacokinetics of etoposide were unaffected by dexrazoxane rescue.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / blood*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Area Under Curve
-
Brain Neoplasms / blood*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / secondary*
-
Carcinoma, Small Cell / blood*
-
Carcinoma, Small Cell / drug therapy
-
Carcinoma, Small Cell / metabolism*
-
Catheters, Indwelling
-
Chromatography, High Pressure Liquid
-
Etoposide / administration & dosage
-
Etoposide / blood
-
Humans
-
Infusions, Intravenous
-
Lung Neoplasms / blood
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / pathology
-
Razoxane / administration & dosage
-
Razoxane / blood